Fecal Incontinence - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 33 pages report, published by Global Markets Direct

Keywords : Fecal Incontinence Therapeutic Products under Development, Key Players in Fecal Incontinence Therapeutics, Fecal Incontinence Pipeline Overview, Fecal Incontinence Pipeline, Fecal Incontinence Pipeline Assessment

Report ThumbnailSeptember-2013
Fecal Incontinence - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Fecal Incontinence - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Fecal Incontinence, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fecal Incontinence. Fecal Incontinence - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Fecal Incontinence.
- A review of the Fecal Incontinence products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fecal Incontinence pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Fecal Incontinence.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fecal Incontinence pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Fecal Incontinence, H2 2013 7
  • Products under Development for Fecal Incontinence - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Mid Clinical Stage Products, H2 2013 11
  • Pre-Clinical Stage Products, H2 2013 12
  • Assessment by Monotherapy Products, H2 2013 18
  • Assessment by Route of Administration, H2 2013 19
  • Assessment by Stage and Route of Administration, H2 2013 20
  • Assessment by Molecule Type, H2 2013 21
  • Assessment by Stage and Molecule Type, H2 2013 22
  • List of Tables
  • Number of Products Under Development for Fecal Incontinence, H2 2013 7
  • Products under Development for Fecal Incontinence - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
  • Comparative Analysis by Pre-Clinical Stage Development, H2 2013 12
  • Products under Development by Companies, H2 2013 13
  • Products under Investigation by Universities/Institutes, H2 2013 14
  • Cook Medical Incorporated, H2 2013 15
  • Norgine Limited, H2 2013 16
  • S.L.A. Pharma AG, H2 2013 17
  • Assessment by Monotherapy Products, H2 2013 18
  • Assessment by Stage and Route of Administration, H2 2013 20
  • Assessment by Stage and Molecule Type, H2 2013 22
  • Fecal Incontinence Therapeutics - Dormant Products 31
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Fecal Incontinence Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Fecal Incontinence 7
  • Fecal Incontinence Therapeutics under Development by Companies 9
  • Fecal Incontinence Therapeutics under Investigation by Universities/Institutes 10
  • Mid Clinical Stage Products 11
  • Comparative Analysis 11
  • Pre-Clinical Stage Products 12
  • Comparative Analysis 12
  • Fecal Incontinence Therapeutics - Products under Development by Companies 13
  • Fecal Incontinence Therapeutics - Products under Investigation by Universities/Institutes 14
  • Companies Involved in Fecal Incontinence Therapeutics Development 15
  • Cook Medical Incorporated 15
  • Norgine Limited 16
  • S.L.A. Pharma AG 17
  • Fecal Incontinence - Therapeutics Assessment 18
  • Assessment by Monotherapy Products 18
  • Assessment by Route of Administration 19
  • Assessment by Molecule Type 21
  • Drug Profiles 23
  • methoxamine - Drug Profile 23
  • Product Description 23
  • Mechanism of Action 23
  • R&D Progress 23
  • clonidine - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • phenylephrine hydrochloride - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • ICEF-15 - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • atropine sulfate - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • NER-1022 - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • Fecal Incontinence Therapeutics - Dormant Products 31
  • Appendix 32
  • Methodology 32
  • Coverage 32
  • Secondary Research 32
  • Primary Research 32
  • Expert Panel Validation 32
  • Contact Us 33
  • Disclaimer 33

Please select a license type

Share

Related Products

Global Markets DirectFecal Incontinence - Pipeline Review, H2 2013Product ThumbnailFecal Incontinence - Pipeline Review, H2 2013, Industry ReportProduct #: 113343
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved